Here are the 10-K annual reports from Petros Pharm Inc (PTPI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PTPI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTPI filings page.
Petros Pharmaceuticals, Inc. files its annual report describing a major shift from erectile dysfunction products to developing a SaaS/SaMD platform to support prescription-to-OTC switches. The 10-K highlights severe liquidity constraints, a going concern warning, and reliance on future capital raises and platform commercialization.
The company exited Stendra and VEDs, assigned related subsidiaries’ assets for the benefit of creditors, and defaulted on a Vivus promissory note, leading to foreclosure on Stendra-related collateral and termination of the Vivus license. Petros now focuses on early-stage, technology-driven Rx-to-OTC solutions without current platform revenue.